Exploring XD And Two Other High Growth Tech Stocks In Asia
As global markets navigate a landscape of economic uncertainty and mixed signals, with tech stocks in the U.S. recently lagging behind broader indices, investors are increasingly turning their attention to Asia's high-growth tech sector for potential opportunities. In this environment, identifying strong stocks often involves looking at companies that demonstrate resilience and adaptability amid changing economic forecasts and geopolitical risks, as these qualities can be crucial for sustaining growth in dynamic markets like Asia.
Name
Revenue Growth
Earnings Growth
Growth Rating
Suzhou TFC Optical Communication
34.71%
33.47%
★★★★★★
Fositek
31.39%
36.95%
★★★★★★
Xi'an NovaStar Tech
30.60%
36.56%
★★★★★★
eWeLLLtd
24.65%
25.30%
★★★★★★
Seojin SystemLtd
31.68%
39.34%
★★★★★★
PharmaResearch
20.19%
26.38%
★★★★★★
giftee
21.13%
67.05%
★★★★★★
JNTC
28.84%
104.08%
★★★★★★
Ascentage Pharma Group International
22.93%
59.90%
★★★★★★
Delton Technology (Guangzhou)
20.25%
29.52%
★★★★★★
Click here to see the full list of 506 stocks from our Asian High Growth Tech and AI Stocks screener.
Let's review some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★★☆
Overview: XD Inc. is an investment holding company that focuses on developing, publishing, operating, and distributing mobile and web games in Mainland China and internationally with a market cap of approximately HK$18.24 billion.
Operations: The company generates revenue primarily through its Game segment, which brought in CN¥2.43 billion, and the TapTap Platform, contributing CN¥1.43 billion. The focus on both game development and the TapTap distribution platform highlights a dual revenue stream strategy within the gaming industry.
XD Inc. has demonstrated a robust trajectory with its revenue expected to surge by 46% to 49% year-over-year, reaching up to RMB 5.04 billion in FY 2024. This growth is complemented by an impressive turnaround from a net loss in FY 2023 to a projected net profit of up to RMB 940 million. The company's commitment to innovation is evident from its substantial investment in R&D, fostering advancements that keep it competitive within Asia's tech landscape. Moreover, XD's earnings are poised for a significant annual increase of approximately 54.6%, outpacing the regional market growth and indicating potential for sustained upward momentum in its financial performance.
Navigate through the intricacies of XD with our comprehensive health report here.
Explore historical data to track XD's performance over time in our Past section.
Simply Wall St Growth Rating: ★★★★★★
Overview: Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China, with a market cap of approximately HK$12.61 billion.
Operations: The company generates revenue primarily through the development and sale of novel small-scale therapies, amounting to CN¥903.03 million.
Ascentage Pharma Group International has shown a notable rebound in its financial performance, with sales soaring to CNY 980.65 million in FY 2024 from CNY 221.98 million the previous year, reflecting a remarkable growth trajectory despite the company's net loss narrowing significantly to CNY 405.43 million from CNY 925.64 million. This improvement is underpinned by strategic R&D investments that fuel innovation across its robust pipeline, highlighted by recent breakthroughs like olverembatinib receiving multiple Breakthrough Therapy Designations in China for critical leukemia treatments. These advancements not only underscore Ascentage's commitment to addressing unmet medical needs but also position it well within the high-stakes biotech sector where it continues to push scientific boundaries at major forums like the AACR Annual Meeting.
Dive into the specifics of Ascentage Pharma Group International here with our thorough health report.
Examine Ascentage Pharma Group International's past performance report to understand how it has performed in the past.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Genew Technologies Co., Ltd. is involved in the global research, development, production, and sale of communication and network products with a market capitalization of CN¥5.73 billion.
Operations: Genew Technologies Co., Ltd. focuses on the global research, development, production, and sale of communication and network products. The company operates with a market capitalization of CN¥5.73 billion.
Genew Technologies Co., Ltd. has pivoted impressively from a net loss to profitability, showcasing a robust annual revenue growth of 30.6% and an even more striking earnings growth of 71%. This performance outpaces the broader Chinese market's average, indicating strong operational efficiency and market acceptance. The shift to profitability is underscored by a recent earnings report for FY 2024, where sales climbed to CNY 950.22 million from CNY 884.41 million the previous year, and net income reached CNY 27.11 million, reversing the prior year's loss of CNY 86.56 million. This financial turnaround is particularly noteworthy in the context of its R&D commitment—integral to its strategic positioning within Asia's competitive tech landscape—highlighting Genew's potential trajectory in influencing regional tech innovation trends.
Unlock comprehensive insights into our analysis of Genew TechnologiesLtd stock in this health report.
Evaluate Genew TechnologiesLtd's historical performance by accessing our past performance report.
Investigate our full lineup of 506 Asian High Growth Tech and AI Stocks right here.
Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2400 SEHK:6855 and SHSE:688418.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
40 minutes ago
- Business Insider
Xiaomi (XIACF): New Buy Recommendation for This Technology Giant
In a report released yesterday, Mark Li from Bernstein maintained a Buy rating on Xiaomi (XIACF – Research Report), with a price target of HK$60.00. The company's shares closed today at $6.84. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Li is a 5-star analyst with an average return of 24.5% and a 61.19% success rate. Li covers the Technology sector, focusing on stocks such as TSMC, Micron, and United Micro. In addition to Bernstein, Xiaomi also received a Buy from Macquarie's Cherry Ma in a report issued on June 4. However, on the same day, J.P. Morgan maintained a Hold rating on Xiaomi (Other OTC: XIACF). Based on Xiaomi's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $111.29 billion and a net profit of $10.92 billion. In comparison, last year the company earned a revenue of $75.51 billion and had a net profit of $4.18 billion
Yahoo
an hour ago
- Yahoo
DBS Maintains Hold Rating on NIO Inc. (NIO) Stock
On June 5, DBS analyst Rachel Miu maintained a Hold rating on NIO Inc. (NYSE:NIO) and set a price target of HK$38.00. The rating update came after the company reported its unaudited fiscal Q1 2025 results on June 3. The analyst stated that the company underwent a 19% year-over-year increase in vehicle revenue driven by a 40% rise in vehicle sales. However, lower average selling price because of a change in the product mix is causing challenges for the company's operations. A fleet of eco-friendly electric cars, a symbol of the company's commitment to sustainability. Miu also reasoned that while NIO Inc. (NYSE:NIO) experienced a minute improvement in its vehicle margin, underperformance in fiscal Q4 2024 and weaker-than-expected guidance for Q1 2025 are anticipated to negatively affect its near-term performance. NIO Inc. (NYSE:NIO) plans to launch a number of new brands and models in 2025, including the ONVO L90 and Firefly. However, the analyst stated that the transition to a new vehicle platform may trigger inconsistent sales trends until the stabilization of the production process. The analyst thus expects the non-GAAP net loss for fiscal year 2025 to widen, prompted by the expected rise in costs associated with the new stores, R&D, and brand marketing. While we acknowledge the potential of LYFT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
8 hours ago
- Yahoo
Salesforce (NYSE:CRM) Declares Quarterly Dividend of US$0.42 Per Share
Salesforce recently affirmed a quarterly cash dividend of $0.42 per share, payable in July 2025. Over the last week, Salesforce's share price remained flat, mirroring the overall market's stable performance despite the broader market experiencing gains, particularly in tech stocks. The market showed resilience with the S&P 500 reaching 6,000 points, bolstered by solid economic data such as the May jobs report. Salesforce's dividend announcement aligns with these broader market sentiments but didn't significantly influence its stock price, reflecting the prevailing investor confidence in robust economic conditions. We've discovered 1 warning sign for Salesforce that you should be aware of before investing here. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent dividend announcement by Salesforce anchors its long-term strategy to retain investor confidence, reflecting robust economic expectations. Over five years, Salesforce's total return—including share price and dividends—was 56.38%, offering a valuable context to its stable performance over the last week. While the company's share price mirrored a flat overall market recently, it indicates that investors may have already priced in the anticipated market resilience and economic growth. Salesforce's shares did underperform the broader US Software industry over the past year, which experienced a higher return of 21.9% compared to the market's 11%. The dividend news alone may not significantly shift revenue and earnings forecasts but underscores the company's commitment to shareholders amidst economic optimism. Analysts forecast Salesforce's revenue to grow by 9% annually over the next three years, with earnings projected to reach US$9.9 billion by 2028. The share price reveals a 32.6% discount compared to the consensus price target of US$354.14, suggesting potential for appreciation if these forecasts are realized. The company's strengthening of AI and data initiatives through investments like Agentforce and Data Cloud may provide further revenue streams, potentially impacting long-term share performance positively. However, risks such as pricing model transitions and external competition remain considerations for Salesforce's future growth trajectory. Click here and access our complete financial health analysis report to understand the dynamics of Salesforce. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:CRM. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
